Interpace Biosciences

Interpace Biosciences CROIC

The Cash Return on Invested Capital (CROIC) of Interpace Biosciences (IDXG) as of Nov 12, 2026 is 24.48 %. In the previous year, Cash Return on Invested Capital (CROIC) was -170.05 % — a change of -114.40% (higher).

CROIC

24.48 %

YoY

-114.40%

Last updated:

Cash Return on Invested Capital (CROIC) of Interpace Biosciences is 2025 24.48 % . Cash Return on Invested Capital (CROIC) of Interpace Biosciences was 2024 -170.05 % . It decreases by -114.40% higher compared to the previous year.

The Interpace Biosciences CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-27.69 USD
Jan 1, 2019
-77.30 USD
Jan 1, 2020
-76.05 USD
Jan 1, 2021
-66.91 USD
Jan 1, 2022
15.44 USD
Jan 1, 2023
-5.78 USD
Jan 1, 2024
-170.05 USD
Jan 1, 2025
24.48 USD
The Interpace Biosciences CROIC history
YEARCROICYoY
24.48 %-114.40%
-170.05 %+2,842.39%
-5.78 %-137.43%
15.44 %-123.07%
-66.91 %-12.02%
-76.05 %-1.62%
-77.30 %+179.12%
-27.69 %-13.47%
-32.01 %-20.25%
-40.14 %-57.40%
-94.22 %+152.89%
-37.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences develops and sells diagnostic clinical and pharma services, focusing on molecular tests for cancer risk evaluation. The company offers five commercialized tests: PancraGEN for pancreatic cancer diagnosis from cysts, PanDNA as a molecular snapshot of limited factors, ThyGeNEXT for thyroid cancer diagnosis using sequencing, ThyraMIR v2 used with ThyGeNEXT for thyroid cancer, and RespriDX to differentiate lung cancer origins. These products are sold to healthcare providers and laboratories seeking advanced diagnostic solutions for cancer risk assessment and treatment planning. Interpace Diagnostics, the company's division, provides bioinformatics and pathology services alongside its molecular tests. The tests target specific cancer types, with PancraGEN and PanDNA addressing pancreatic cancer, ThyGeNEXT and ThyraMIR v2 for thyroid cancer, and RespriDX for lung cancer differentiation. Healthcare institutions and physicians utilize these services to improve diagnostic accuracy and patient outcomes in oncology care. The company's revenue streams come from the direct sale of its molecular diagnostic tests and associated services to medical professionals and healthcare facilities. These services are positioned for precision medicine applications, supporting cancer diagnosis, prognosis, and treatment decisions. The business model relies on the clinical utility and technological innovation of its tests to drive adoption among healthcare providers focused on oncology diagnostics. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

Cash Return on Invested Capital (CROIC) of Interpace Biosciences is 24.48 % in 2025.

Cash Return on Invested Capital (CROIC) of Interpace Biosciences changed from -170.05 % to 24.48 %, representing a -114.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Interpace Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Interpace Biosciences

All Key Metrics — Interpace Biosciences